Table 1 Patient Characteristics on Prospective Trial

From: Pre-operative stereotactic radiosurgery and peri-operative dexamethasone for resectable brain metastases: a two-arm pilot study evaluating clinical outcomes and immunological correlates

 

Study Arm

 

Covariate

A (N = 10)

B (N = 11)

P-value

Age

63.05 ± 7.91

57.53 ± 12.85

0.257

Gender

 Female

5 (50)

7 (63.64)

0.670

 Male

5 (50)

4 (36.36)

 

ECOG

 <2

9 (90)

7 (63.64)

0.311

 >=2

1 (10)

4 (36.36)

 

Primary Site

 NSCLC

3 (30)

2 (18.18)

0.893

 Breast

1 (10)

3 (27.27)

 

 Melanoma

3 (30)

4 (36.36)

 

 GI

1 (10)

1 (9.09)

 

 Other

2 (20)

1 (9.09)

 

Previous IO therapy

 No

7 (70)

9 (81.82)

0.635

 Yes

3 (30)

2 (18.18)

 

Preop SRS dose (Gy)

 12

0 (0)

1 (9.09)

0.601

 13

1 (10)

2 (18.18)

 

 14

2 (20)

1 (9.09)

 

 16

2 (20)

2 (18.18)

 

 18

3 (30)

1 (9.09)

 

 24

0 (0)

3 (27.27)

 

 27

2 (20)

1 (9.09)

 

Preop SRS fractions

 1

8 (80)

7 (63.64)

0.635

 3

2 (20)

4 (36.36)

 

WBC

9.18 ± 4.52

11.2 ± 5.69

0.382

ANC

7.37 ± 3.94

8.39 ± 4.88

0.608

Lymphocytes

1.49 ± 0.68

1.76 ± 2.1

0.706

SRS GTV volume (cm3)

17.3 ± 14.58

29.44 ± 18.26

0.111

Days from SRS to surgery

3.5 ± 3.31

4.55 ± 2.94

0.453

  1. The p-value is calculated by two-way ANOVA for numerical covariates; and chi-square test or Fisher’s exact for categorical covariates, where appropriate. Values for categorical factors are presented as numbers (percentage), and for continuous variables are presented as mean ± standard deviation. All tests are two-sided.
Back to article page